HNHelmut Niederhofer

Helmut Niederhofer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Helmut Niederhofer has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Comparison of disulfiram and placebo in treatment of alcohol dependence of adolescents

    by Helmut Niederhofer, Wolfgang Staffen

    About 50% of alcoholic patients relapse within 3 months of treatment. Previous studies have suggested that disulfiram may help to prevent such relapse. The aim of our study was to assess the efficacy and safety of long‐term disulfiram treatment in alcohol dependence of adolescents. In this double‐blind, placebo‐controlled study we recruited 26 adolescents, aged 16–19 years, with chronic or episodic alcohol dependence. Patients were allocated treatment randomly with disulfiram (200 mg daily) or placebo for 90 days. Patients were assessed on the day treatment started and on days 30 and 90 by interview, self‐report, questionnaire and laboratory screening. Patients were classified as abstinent, relapsing or non‐attending. Time to first treatment failure (relapse or non‐attendance) was the primary outcome measure. The disulfiram (n = 13) and placebo (n= 13) groups were well matched in terms of baseline demographic and alcohol‐related variables. Thirteen disulfiram‐treated and 13 placebo‐treated patients completed the treatment phase; seven (1 vs. 6) relapsed, five (3 vs. 2) refused to continue treatment, three (1 vs. 2) had concurrent illness and two (1 vs. 1) had adverse side effects. At the end of treatment, seven disulfiram‐treated and two placebo‐treated patients had been abstinent continuously (p = 0.0063). Mean cumulative abstinence duration was significantly greater in the disulfiram group than in the placebo group [68.5 (SD 37.5) vs. 29.7 (19.0) days; p = 0.012]. Apart from occasional diarrhoea, there was no difference in side effects between groups. In some cases, disulfiram may be an effective and well‐tolerated pharmacological adjunct to psychosocial and behavioural treatment programmes for treatment of adolescent alcohol‐dependent patients.


  • An open trial of buspirone in the treatment of attention‐deficit disorder

    by Helmut Niederhofer

    Objective: Medications such as clonidine have been shown to facilitate calming, to enhance frustration tolerance, and to reduce aggression in attention deficit disorder (ADD) patients. The use of buspirone was studied as an alternative because of its longer excretion half‐life, decreased sedative side effects and more selective binding profile.Method: Eight psychiatric outpatients diagnosed with ADD were rated at baseline and while taking buspirone to determine its efficacy as a treatment for ADD. Comparisons of Wender‐Utah ratings within subject were used to measure behavioural changes in the subjects.Results: During buspirone treatment, the patients' mean scores improved significantly overall and in hyperactivity, inattention and immaturity factors.Conclusions: This preliminary study indicates that buspirone might be a beneficial and useful treatment of ADD, reducing hyperactive behaviours and enabling greater attentional ability with minimal side effects. Copyright © 2003 John Wiley & Sons, Ltd.


    • 1 June 2003
      • Vol. 15, 3-6

    Selegiline and methylphenidate in treatment of ADHD.

    by Helmut Niederhofer

    A lack of perseverance, poor attention and poorly modulated behaviour are important criteria of Attention deficit hyperactive disorder. Instructions often have to be repeated, sometimes even by different family members before a child with ADHD attends and complies. The hyperkinetic child might cause less disagreement in families with high coherence. Methylphenidate is quite effective in psychopharmacological treatment of ADHD. Selegiline has a longer half-life time and seems to be as effective as Methylphenidate. Families of 15 boys (age 6 to 12 years), diagnosed with ADHD using the Mannheim;s Parents Interview and teacher;s form of the Conners Scale, who were treated with Methylphenidate, were compared with a matched group of 15 boys treated with Selegiline. Methylphenidate was administered four times/day, Selegiline was administered twice a day only. The Mann-Whitney-U-Test suggested, that there was no significant difference of improvement between Selegiline and Methylphenidate.


    • 1 June 2003
      • Vol. 15, 7-12

    About the association between attachment and temperament at the age of 6 months.

    by Helmut Niederhofer, Alfons Reiter

    This study investigates the association between the mother-child attachment (0.6 years) and the child;s temperament at that age. A significant correlation of secure attachment and easy children as well as of insecure ambivalent/avoidant attachment and difficult children was expected. 105 healthy children, aged 0.5-0.8 months, were assessed by a semi-structured interview, based on Axis II (Zero to Three, 1994), and the guidelines of Thomas et al. (1968). Data were compared by correlation analysis and Mann-Whitney U-Test. Ambivalent attachment is highly associated with "difficult" and "slow to warm up" temperament. There is almost no association between secure attachment and easy children. Avoidance does not seem to be associated with temperament factors. Insecure attached children seem to show temperament disorders and vice versa. This circular process can be stopped by attachment improving programs: improving the attachment may make children "easy". Secure attachment may not stand for easy children. Altogether, attachment and temperament are two separate behavior conducts, that are only poorly associated.

  • Retracted

    RETRACTED ARTICLE: Acamprosate and its efficacy in treating alcohol dependent adolescents

    by Helmut Niederhofer, Wolfgang Staffen

    Background: About 50 % of adult alcoholic patients relapse within 3 months of treatment. Previous studies have suggested that acamprosate may help to prevent such relapse. The aim of our study was to assess the efficacy and safety of long-term acamprosate treatment in alcohol dependence of adolescents. Methods: In this, double-blind, placebo-controlled study, we recruited 26 patients, aged 16–19 years, with chronic or episodic alcohol dependence. Patients were randomly allocated treatment with acamprosate (1332 mg daily) or placebo for 90 days. Patients were assessed on the day treatment started and on days 30, and 90 by interview, self report, questionnaire, and laboratory screening. Findings: 13 acamprosate-treated and 13 placebo-treated patients completed the treatment phase: of those withdrawn, 11 (1 vs 6) relapsed, 5 (3 vs 2) refused to continue treatment, 3 (1 vs 2) had concurrent illness, and 2 (1 vs 1) had adverse side-effects. At the end of treatment, 7 acamprosate treated and 2 placebo-treated patients had been continuously abstinent (p = 0.0076). Mean cumulative abstinence duration was significantly greater in the acamprosate group than in the placebo group (79.8 [SD 37.5] vs 32.8 [19.0] days; p = 0.012). Interpretation: Acamprosate is an effective and well-tolerated pharmacological adjunct to psychosocial treatment programmes.


  • Tianeptine: a novel strategy of psychopharmacological treatment of children with autistic disorder

    by Helmut Niederhofer, W. Staffen, A. Mair

    Objectives: Many autistic children have problems of eye contact and expressive language that limit the effectiveness of educational and behavioural interventions. Few controlled psychopharmacological trials have been conducted in autistic children to determine which agents may be effective for these associated features.Methods: Twelve male children (7.3 ± 3.3 years) with autistic disorder, diagnosed by ICD‐10 criteria, completed a placebo‐controlled, double‐blind crossover trial of tianeptine, which lasted for 12 weeks. Subjects were included in the study if their eye contact and expressive language was inadaequate for their developmental level. Subjects had not tolerated or responded to other psychopharmacological treatments (neuroleptics, methylphenidate, clonidine or desipramine).Results: Teacher ratings on the aberrant behaviour checklist irritability, stereotypy and inappropriate speech factors were lower during treatment with tianeptine than during treatment with placebo. Clinician ratings (children's psychiatric rating scale autism, anger and speech deviance factors; children's global assessment scale; clinical global impressions efficacy) of videotaped sessions were not significantly different between tianeptine and placebo.Discussion: Tianeptine were modestly effective in the short‐term treatment of irritability in some children with autistic disorder. Copyright © 2003 John Wiley & Sons, Ltd.


  • Retracted

    A placebo-controlled study of lofexidine in the treatment of children with tic disorders and attention deficit hyperactivity disorder

    by Helmut Niederhofer, Wolfgang Staffen, Alois Mair

    This study evaluated the efficacy and safety of Lofexidine in treating children with tic disorders and attention deficit hyperactivity disorder (ADHD). Subjects from a specialty tic disorders clinic were randomly assigned to receive 8 weeks of treatment with lofexidine or placebo under double-blind conditions. Follow-up visits occurred every 2 weeks for safety monitoring and dose adjustment. Fourty-four medication-free subjects (41 boys and three girls; mean age of 10.4 years) with ADHD, combined type, and a tic disorder participated. After 8 weeks of treatment, lofexidine was associated with a mean improvement of 41% in the total score on the teacher-rated ADHD Rating Scale compared to 7% improvement for placebo. Eleven of 22 subjects who received lofexidine were blindly rated on the Clinical Global Scale-Improvement as either much improved or very much improved compared to none of 22 subjects who received placebo. The mean score on the parent-rated hyperactivity index improved by 29% in the lofexidine group and 18% in the placebo group, which was not a significant difference. On the Continuous Performance Test, commission errors decreased by 25% and omission errors by 20% in the lofexidine group, compared with increases of 33% in commission errors and of 36% in omission errors in the placebo group. Tic severity decreased by 27% in the lofexidine group, compared to 0% in the placebo group. One lofexidine subject with sedation withdrew at week 4. Lofexidine was associated with insignificant decreases in blood pressure and pulse. Lofexidine appears to be a safe and effective treatment for children with tic disorders and ADHD.


  • Galantamine may be effective in treating autistic disorder

    by Helmut Niederhofer, W Staffen, A Mair


    • 1 January 2001
      • Vol. 151, 327-8

    [Therapy of tic disorders apparently of organic origin in a multi-morbid 5-year-old patient with lofexidine (Britlofex) and clonidine (Catapressan)].

    by H Niederhofer

    We report about a five year-old patient suffering from tics and ADHD (attention deficit hyperkinetic disorder), aggressions, depression and emotional disorder. Furthermore, an epileptic focus and perinatal encephalopathy were diagnosed. Lofexidine (Britlofex) medication did not reduce Tic symptomatology, but showed remarkable sedative effects. Family therapy and Clonidine (Catapressan) medication reduced symptomatology significantly.